chrisvoncsefalvay/vaers-outcomes huggingface dataset:
ED visit 1/21/21: Patient presents today with constellation of symptoms including some myalgias with low-grade fevers at 100.9 degrees, feeling some wheezing as well as a fine rash across her upper chest, she states that she had the vaccine for COVID-19 2 days ago, yesterday she started experiencing the symptoms, she tried using her inhaler for the wheezing, she utilize Tylenol for her fever and she also took Benadryl for the itching on the skin.  These improved her symptoms.  They seem to come back later in the day after the medicines were wearing off so she presented here for further evaluation.  She denies nausea vomiting abdominal pain.  Patient believes she had COVID-19 around Thanksgiving 2020, she was not test at that time but had symptoms consistent with COVID-19 loss of taste and smell and her grandmother whom she was around at that time did test positive. Constitutional: patient in no active distress, resting in room Skin: Skin is warm and dry, normal for ethnicity, no rash visualized. Head: Atraumatic, normocephalic Neck: Normal range of motion. Neck supple.  Trachea centerline, no lymphadenopathy Mouth: Oropharynx is clear to inspection, uvula centerline, no tonsillar exudate Cardiovascular: No peripheral edema, normal rate and rhythm, no murmur Pulmonary/Chest: Effort normal.  Mild expiratory wheeze posteriorly bilaterally at the end of expiration, good respiratory excursion. Abdomen: Soft, nontender negative Murphy's negative McBurney's, no guarding, negative rebound Musculoskeletal:  Normal ROM, no deformity.    Neurological: Patient is alert.  No focal neurologic deficits diphenhydrAMINE (BENADRYL) capsule 25 mg (25 mg oral Given 1/21/21 1333) dexAMETHasone (DECADRON) vial 10 mg (10 mg oral Given 1/21/21 1400)
Vaccine was given in the arm close to the elbow not in the deltoid. My daughter was complains of numbness and the sight was swollen and red for two days. I applied Ice for two days to get the swollen down.
Episodes of syncope; Initial information was received on 03-Aug-2020 regarding an unsolicited valid serious case received from an other health professional.  This case involves a 17-years-old female patient who experienced episodes of syncope (syncope), while she received vaccine MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA].  The patient's medical history, past medical treatment(s), vaccination(s) and family history were not provided. No other concomitant vaccine was received.   On 31-Jul-2020, the patient received a 0.5 mL once dose of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE injection (lot U6596AB and expiry date 24-May-2021) via unknown route in the left arm for prophylactic vaccination.  On 31-Jul-2020, the patient developed a serious episodes of syncope (syncope) immediately on same day after the administration of MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE. This event was assessed as medically significant.  Case details: Reporter stated that, they had three episodes of syncope right after administration of Menactra with three different patients from the same batch of Menactra.  The patient was doing well at the time of report.  Details of laboratory data were not reported.  Final diagnosis was syncope.  It was not reported if the patient received a corrective treatment.  On an unknown date, the patient was recovered from the event of syncope. It was reported patient was doing well.; Sender's Comments: This case involves a 17-years-old female patient who experienced syncope on same following vaccination with MENACTRA vaccine. The time to onset was compatible. However, detailed additional information of past medical treatments, concomitant therapies, past vaccination and tolerance, concurrent conditions, laboratory data were not reported. Based upon the reported information, the role of the vaccine cannot be assessed. Missing data needed for further assessment of the case.
Patient came by the pharmacy with a golf ball size firm, red node on her left arm between her bicep and tricep approximately 7 hours after her vaccine. She reported this node was very itchy and uncomfortable. Patient was instructed to use ice, ibuprofen, and diphenhydramine to treat. Also instructed that if she experienced fever, or if the reaction spreads down her arm or toward her chest she go to the ER.
No adverse event; Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 days beyond use date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 days beyond use date) and NO ADVERSE EVENT (No adverse event) in a 58-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 052D22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 28-Nov-2022, the patient received third dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On 28-Nov-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 days beyond use date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 days beyond use date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Moderna vaccine (more or less 170 - monovalent and 20 bivalent) which were beyond the 30 days beyond use date).    No concomitant medications were reported.   Before use date reported was 17-Nov-2022.  No treatment details were reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-704416 (Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 24-Jan-2023: Live follow-up received: Patient details and vaccination details were updated. On 24-Jan-2023: Live follow-up contains no new information.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-704416:Master case
Within 30 seconds to 1 minute, after receiving the above vaccines while walking towards the hallway the child gently slid onto the floor braced by the wall, a bookcase, and her father. While sitting upright at 90 degrees on the floor she stated that she was going to vomit. Scant amount of emesis noted. Flatus noted. She was assisted to a left side laying position on a floor mat which she was able to transfer herself to with direction. BP left arm 80/60. No s/s of anaphylaxis  noted. Pt A&Ox3. No further emesis noted. Pt was able to sip juice, stand up and ambulate herself to the chair in hallway with her father in arm's reach. She ate a snack s issue and finished juice. This RN suspects an episode of syncope occurred. This RN educated ch's father on self care measures. Pt was weighed in the case of needing acetaminophen determined by weight.
Bad headache within 24 hours. lasted 8 weeks. then 8 weeks later,  both legs became paralyized,  up to my body, arms and lower lip. Could not breath . was on respirator for 60 days. hospitalized from November 25 to May 15th of 2022.
SEVERELY DRY SKIN; ACHY BACK; ITCHINESS IN LEGS/ARMS/BUTTOCK/BACK/BELLY/UNDER ARM; This spontaneous report received from a patient concerned a 72 year old male. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine  (suspension for injection, route of admin not reported, batch number: Unknown, and batch number: 042A21A expiry: UNKNOWN) dose was not reported, administered on 14-MAY-2021 for prophylactic vaccination. No concomitant medications were reported. On 22-MAY-2021, the subject experienced severely dry skin. On 22-MAY-2021, the subject experienced achy back. On 22-MAY-2021, the subject experienced itchiness in legs/arms/buttock/back/belly/under arm. The action taken with covid-19 vaccine  was not applicable. The patient had not recovered from severely dry skin, achy back, and itchiness in legs/arms/buttock/back/belly/under arm. This report was non-serious.
HEADACHE; This spontaneous report received from a patient concerned a 61 year old female. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805018 expiry: UNKNOWN) dose was not reported, administered on 26-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 28-APR-2021, the subject experienced headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from headache. This report was non-serious.
Patient developed swollen lymph nodes on her neck/throat the day after receiving SHINGRIX. She was so uncomfortable due to the swelling that she was not able to go to work that day. Patient reported feeling feverish and experiencing flu-like symptoms.
patient given COVID-19 vaccine Moderna dose 1 and 2 in past. COVID-19 Pfizer 3rd dose was given. patient denies any adverse affects at this time.
2 hrs after given vaccine, couldn't move (R, arm very painful, rec. cortisone inj a wk later, with very little results saw natural dr, Oct saw ortho, said inj was given into bursa sac, given another cort. inj - still don't have full range of motion still having pain
pt recv vax & devel subacute encephalopathy manifested by fever, status epilepticus & apnea;pt hosp & tx w/meds;made a remarkable recovery but had residual minimal hemiparesis & truncal ataxia;dx chediak-Higashi synd triggered by vax
2/14 pain-L ankle, weakness in same ankle throughout day-resolved. 2/15 feverish-resolved. 2/17 red pimple-like dots lower abdo, both arms-resolved. 2/19 feverish, pressure devel on R side of head-resolved w/ excep of fever.
On Thursday, March 18, 2021 client  received his first dose of Pfizer COVID vaccine (LOT # ER2613, EXP 7/2021) at approximately 2:45pm by vaccinator. During assessment of screening questions, client stated he has a history of anxiety when getting vaccinations. After vaccine was administered, client stated he "felt anxious and dizzy." Vaccinator took his pulse at this time: 88bpm. Client was given water and sat at vaccination table for approximately 15 minutes. At 3:00pm, client walked with a steady gait to the Observation Area and EMT performed the following vitals assessment: At 3:05pm, vitals: BP: 130/p, HR: 60, RR: 13, Skin: dry, pink, warm. Vitals at 3:10pm: BP: 128/p, HR: 58, RR: 13, skin: dry, pink, warm. Vitals at 3:15pm: BP: 132/p, HR: 60, RR: 14, skin: dry, pink, warm. (p= over palpation-cuff too small for client). Client was observed watching videos on his phone and stated to EMT his anxiety had significantly lowered. No further interventions indicated. Client was educated by Lead RN & EMT on signs and symptoms of adverse reactions and when to go to the ED/call MD. Client left vaccination site with a steady gait and was driven home by his mother.
Multiple hives on trunk and upper extremities. Largest on (L) flank 14cm x 10cm. None surrounding injection site on (L) deltoid.
Information has been received from a physician concerning a 7-month-old male who was vaccinated PO with the second 2.0 ml dose of Rotateq. The physician reported that, 11 days after receiving the second dose, the patient developed intussusception. The patient was taken to the Emergency Room (ER) where the intussusception was reduced by an enema. It was unknown if the patient was hospitalized. At the time of this report, the outcome was unknown. Upon internal review, intussusception was determined to be an other important medical event. Additional information has been requested.   4/13/07 Received MDs report to manufacturer which included all missing information.  VAERS database updated. 4/27/07 Received medical records from hospital of 3/26/07 & clinic of  11/06-3/15/07 which reveal patient experienced on 3/26/07: abdominal pain, lethargy, malaise.  US revealed IS which was reduced.  Observed for 23 hrs & d/c to home. FINAL DX: ileocolic intussusception, successfully reduced by hydrostatic enema.
patient felt light headed and did not feel right after the vaccine. she works and went over there after the vaccine and called to say she wasnt feeling well. we advised her to sit down with her head between her knees and call another associate to cover for her. when we went over an checked on her the facility was closed. we are being told she went to the er
12/25/2021 evening once we checked her in to ER. The doctor saw that she had hives and she had Benadryl 10ml 2 hours afterward it starting fading. They started slowing disappearing after she was discharged the hives were disappearing. They were all gone by the next morning 12/26/2021. First time we had seen hives on her body, no new foods or nothing new introduced. We took her to follow up care December 27th with the Doctor since all hives were gone. I showed pictures to the Doctor, and we were referred to an allergist. I have not yet made appointment.
Patient came to pharmacy asking for quadrivalent flu shot, however, was administered the high dose flu shot. Patient and doctor are aware. No adverse event currently reported.
Pt. states that after receiving the 3rd dose Booster of Pfizer 10/16/2021(also receiving the High-Dose Influenza vaccine), started experiencing symptoms 10/17/2021 (02:00am) fever, chills, muscle aches, headaches, and arm pain. 10/18/2021 dizziness, nausea, and fatigued. No noted Primary visit/communication.
Fatigue; Temperature of 99.4; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (Fatigue) and PYREXIA (Temperature of 99.4) in an 83-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 21-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Feb-2021, the patient experienced FATIGUE (Fatigue) and PYREXIA (Temperature of 99.4). At the time of the report, FATIGUE (Fatigue) and PYREXIA (Temperature of 99.4) outcome was unknown.            No concomitant medications were provided No treatment information provided
COVID-19 Vaccine) (batch nos. 013M20A and 029K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 25-Feb-2021, the patient experienced VACCINATION SITE DISCOLOURATION (reaction has improved but it still has some discoloration), VACCINATION SITE WARMTH (felt hot/ had heat), VACCINATION SITE PRURITUS (Had very severe itching) and VACCINATION SITE RASH (A rash that was really red and got bigger each day,encompassed 2/3 of her arm and the width of it was as wide as the palm of the hand). The patient was treated with PARACETAMOL (TYLENOL) at a dose of UNK dosage form and IBUPROFEN at a dose of UNK dosage form. At the time of the report, VACCINATION SITE DISCOLOURATION (reaction has improved but it still has some discoloration) had not resolved and VACCINATION SITE WARMTH (felt hot/ had heat), VACCINATION SITE PRURITUS (Had very severe itching) and VACCINATION SITE RASH (A rash that was really red and got bigger each day,encompassed 2/3 of her arm and the width of it was as wide as the palm of the hand) was resolving.            Patient used unspecified medication for itching. No relevant concomitant medications were reported.   This case was linked to MOD-2021-041015 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 03-May-2021: Additional information received captured no new information.
Within about 40 minutes of the shot, my daughter started complaining of being itchy at the injection site. Then it quickly turned into itchy everywhere - mainly right side of her body - arm, hand, thumb, neck, cheek, and then about 15 minutes later it was at her legs and feet. She developed a slight bump on her chin that was itchy but then it subsided within about 10 minutes. By the time it had been about 75 minutes since the injection, she seemed to be less red everywhere and was only occasionally itching. She wasn?t as bothered by it at that point. It?s now 6 hours later and she seems to be fine, with random itching intermittently.
flu like symptoms; Fever; This spontaneous case was reported by a consumer and describes the occurrence of INFLUENZA LIKE ILLNESS (flu like symptoms) and PYREXIA (Fever) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (flu like symptoms) and PYREXIA (Fever). At the time of the report, INFLUENZA LIKE ILLNESS (flu like symptoms) and PYREXIA (Fever) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication were not reported. Treatment medication were not reported.  This morning, the patient had the weak/tired Covid-19 feeling when the patient had it in May. Now the patient is very nauseated, The patient have a grandson with a fever, one with flu like symptoms, son-in-law same.  The patient's husband and daughter are so far fine.  How long does this last  This report 1s for patient# 3   Reporter did not allow further contact
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. Concurrent condition and medical history were not reported. On 21-JUL-2015, the patient was vaccinated with improperly stored doses of MMR II (lot # K003806, expiration date) (Strength, route and dose were not reported); and (Oka/Merck) VARIVAX (Lot # K021487, expiration date 03-NOV-2016) (Strength, dose and route were not reported). No adverse reactions were reported. This is one of several reports from the same source. Additional information has been requested.
Pain at injection site left arm; Fever 101.6; Reduced size of Lipoma right armpit; This spontaneous case was reported by a consumer and describes the occurrence of THERAPEUTIC RESPONSE UNEXPECTED (Reduced size of Lipoma right armpit), VACCINATION SITE PAIN (Pain at injection site left arm) and PYREXIA (Fever 101.6) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 016B21A and 036A21A) for COVID-19 vaccination.     Concurrent medical conditions included Lipoma (finding a fatty lymph node under her right arm,size was 4.5 x 4.5 cm.).   On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 31-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 31-Mar-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced THERAPEUTIC RESPONSE UNEXPECTED (Reduced size of Lipoma right armpit). On 01-Apr-2021, the patient experienced VACCINATION SITE PAIN (Pain at injection site left arm) and PYREXIA (Fever 101.6). At the time of the report, THERAPEUTIC RESPONSE UNEXPECTED (Reduced size of Lipoma right armpit), VACCINATION SITE PAIN (Pain at injection site left arm) and PYREXIA (Fever 101.6) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-Apr-2021, Body temperature: 101.6 (High) 101.6. On 01-Apr-2021, Magnetic resonance imaging: normal (normal) confirmed size of Lipoma was greatly reduced.         No concomitant medication details was reported. No treatment medication details was reported. Action taken with mRNA-1273 in response to the events was not applicable.
Pain and tingling in right arm, dizzyness, light-headed, headache, nausea and weakness at the time of administration. Severe pain and weakness in arm resulted in return visit to clinic two days after vaccination. Doctor prescribed steroids but directs patient not to take them unless she really needed them as they could interfere wit efficacy of meningococal vaccine. Alternated Tylenol and Advil continuouly for the following 4 days and began taking steroid on Sunday because pain was still severe and she was unable to move her arm without severe pain. Steroids helped lessen pain and reliance on the NSAIDS, but she continues to need pain medication (though less) today, which is 6 days after vaccination.
Vaccine expired on 12-Apr-2022 was initially stored in refrigerator on 13-Apr-2022; A patient was administered an expired dose; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (A patient was administered an expired dose) and PRODUCT STORAGE ERROR (Vaccine expired on 12-Apr-2022 was initially stored in refrigerator on 13-Apr-2022) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001J21-2a) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (A patient was administered an expired dose). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine expired on 12-Apr-2022 was initially stored in refrigerator on 13-Apr-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (A patient was administered an expired dose) and PRODUCT STORAGE ERROR (Vaccine expired on 12-Apr-2022 was initially stored in refrigerator on 13-Apr-2022) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medication was reported.  It was reported that the patient was administered with the 2nd booster dose on 13-Apr-2022. Date the vial was initially stored in the refrigerator was on 13-Apr-2022. The vial did not undergo any temperature excursions. Patient did not experience any symptoms.  No treatment medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 13-Apr-2022: Follow-up document received includes no new information.
Achy muscles on the first day after the 2nd dose.  The following day, sever chills, achy muscles (difficulty walking/climbing stairs) for about 3 days,  bad headaches that lasted about 4 days off and on, and very disoriented.
Bled after injection, hurt, got a lump & bruise afterward. Hurt for weeks afterward. Hurt ever since. "Like a torn muscle" burns every day. Can't swim effectively now & after. Patient now says she was told not to have vaccines (never get annual flu shot) by her doctor because of her many conditions but wanted typhoid because of travel.